We performed a randomized, controlled trial of intravenous immune globulin (respiratory syncytial virus [RSV1 neutralizing [Ntl antibody titer of 1:950 in 5% solution) to evaluate protection against RSV-induced disease over two respiratory virus seasons. Forty-nine children (mean age at enrollment, 4.5 months) with severe congenital heart disease or bronchopulmonary dysplasia were randomized as follows. Twenty-four patients were followed as controls and received no immune globulin. Twenty-five patients received monthly infusions of immune globulin at a dose of 500 mg/kg of body weight. There was a similar distribution between groups of patients with heart disease and bronchopulmonary dysplasia. There were 12 culture-proven RSV infections, 6 in the prophylaxis group and 6 in the control group. There was a trend toward less severe RSV illness in immune globulin recipients, as measured by length of hospitalization. Four of the six immune globulin recipients were hospitalized for a total of 35 days (mean, 8.8 5.0 days) because of RSV illness, in contrast to 51 hospital days (mean, 12.8 7.6 days) among RSV-infected controls. We conclude that monthly infusions of standard immune globulin containing RSV Nt antibodies may be safely administered to high-risk children, but that standard intravenous immune globulin does not contain sufficient RSV Nt antibody titer to fuly protect against severe RSV illness.
Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infections in infants and young children (1) . Several groups of infants and children are recognized to be at particular risk for severe RSV illness. These include infants with congenital heart disease, particularly those with pulmonary hypertension, and infants with bronchopulmonary dysplasia, the chronic lung disease of prematurity (5, 7, 16) . Active immunization against RSV has proceeded cautiously because there has been concern that augmentation of the immune response may result in pulmonary complications similar to those which occurred in RSVinfected recipients of the formalin-inactivated RSV vaccine (2, 3, (12) (13) (14) . Attempts to develop a safe and immunogenic RSV vaccine have met with only limited success (8) .
As an alternative to active immunization, the role of passive immunization in the prevention of serious RSV illness has been examined. Studies in cotton rats and owl monkeys indicate that immunoprophylaxis is a safe and effective method of preventing RSV lower respiratory tract disease (10, 11, 19) . Human epidemiologic studies demonstrate that term neonates may experience less severe RSV disease in the first few weeks of life when maternal neutralizing antibody levels are highest. Severe RSV lower respiratory tract illness tends to occur when antibody titers have fallen to low levels (4, 9, 15, 18) . These observations in animals and humans suggest that serum neutralizing antibodies to RSV may play a beneficial role in preventing RSV lower respiratory tract disease. On the basis of these con-* Corresponding author.
siderations, we conducted a randomized, controlled immunoprophylaxis trial using a standard intravenous immune globulin to assess protection against RSV illness in high-risk children.
(The study described here was presented in part at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., 29 September to 2 October 1991.)
MATERIALS AND METHODS
Patients under 24 months of age were recruited from the Pediatric Cardiology and Pulmonary services at the New England Medical Center. An attempt was made to enroll patients in the first year of life, because these infants are at greatest risk of severe disease (1) . Cardiac patients were enrolled if they had severe congenital heart disease, particularly with pulmonary artery hypertension (16) . Patients with bronchopulmonary dysplasia were eligible for participation if they required supplemental oxygen during the 4 months preceding enrollment in the study (5 immune globulin every 4 to 5 weeks at a dose of 500 mg/kg of body weight. This schedule was based on the estimated immune globulin half-life of 21 days. The volume of the infusion was 10 ml/kg, at a concentration of 50 mg/ml. Most patients received their first infusion in December, with the last infusion given in April. Intravenous immune globulin was infused over 2 to 4 h either in the outpatient clinic under close nursing supervision or in the inpatient units for those participants who were hospitalized for other reasons.
The number of days of illness in patients and family members was monitored during weekly telephone calls and visits to the clinic. All participants were contacted once a week by telephone until 1 May by a nonblinded study nurse who inquired about fever, cough, new-onset wheezing, rhinitis, and respiratory rate. Infants were clinically evaluated only during their months of participation during the respiratory virus season. Outpatients with respiratory symptoms were asked to come to the clinic so that nasal washings could be obtained for an RSV rapid antigen assay and a viral culture (16) . Inpatients were seen on a regular basis, and viral studies were performed on symptomatic patients. Serum was obtained at the time of enrollment and was frozen at -20°C. Subsequent serum specimens were obtained from 17 children at least 1 month after the end of the respiratory virus season to assess immunoglobulin A (IgA) conversion. Peak (6 h after an infusion) and trough (just prior to subsequent infusion) serum specimens were obtained from 11 patients to assess RSV neutralization antibody titers. Virus neutralization titers to RSV subtype A were performed by using a virus plaque reduction assay as described previously (21) . IgA and IgG antibody titers were determined by quantitative immunodiffusion.
Because caretakers were not blinded to the infants' randomization status, no attempt was made to evaluate the difference in severity of symptoms between the two groups. The end points used were days of hospitalization as a result of respiratory symptoms, because discharge was decided by physicians who were not involved in the study.
Statistical comparisons between groups were conducted by chi-square analysis, Fisher's exact test, and the Student t test when appropriate. A P value of less than 0.05 was considered significant. The power analysis was based on the use of the two-sample t test for independent samples.
RESULTS
Enrollment. Forty-nine children were enrolled in the study during two wintertime RSV seasons: 30 November 1988 to 1 May 1989 and 30 November 1989 to 1 May 1990. The distribution of cardiac and pulmonary disease among the 24 infants in the control group and the 25 infants in the placebo group is shown in Table 1 . Several children had more than one cardiac lesion. Most infants received their first infusion in December, although some were enrolled later in the respiratory virus season. The average age at enrollment and the average number of months of observation for infants in the two groups were not significantly different, and the total number of viral cultures were also comparable between the groups (Table 1) . There appeared to be more days of symptomatic illness in family members in the prophylaxis group than in the control group, although this difference was not statistically significant.
Virus isolation. RSV was isolated on six occasions from five different patients in the control group and on six occasions in five patients who received immunoprophylaxis. For one symptomatic patient in the control group, both adenovirus and an enterovirus were isolated from a nasal washing. Influenzavirus type A was isolated from a symptomatic child in the prophylaxis group. Respiratory illness. Among the 24 control patients, there were 71 episodes of respiratory illness and 42 viral cultures were obtained. In comparison, among the 25 infants who received immunoprophylaxis, there were 74 episodes of respiratory illness and 37 cultures were obtained. There was no effect of immune globulin administration on the number of non-RSV respiratory illnesses among the infants in the two groups. Furthermore, the average number of days of respiratory symptoms per patient was not different between the two groups ( Table 2 ). Three patients in the control group and six patients in the intravenous immune globulin group were hospitalized for at least 75% of their period of observation for medical reasons not related to infectious causes; these patients were therefore excluded from analysis. No significant differences in hospital days between groups was observed among the remaining children ( Table 2) .
The exclusion of hospital day comparisons of infants who had culture-documented RSV infection 1 month preceding enrollment in the study was made because of concern that a previous RSV infection might alter susceptibility to a second RSV infection. No statistical difference between mean hospitalization days was observed between control and immune globulin-treated children (Table 2) . However, the number of hospitalization days because of respiratory symptoms was fewer in the prophylaxis group by 64%.
There were 12 culture-documented RSV infections among infants in the two groups. In the control group, there were six RSV infections in five patients, resulting in four hospitalizations for a total of 51 hospital days. In the prophylaxis group, there were six RSV infections in five patients, four of whom required hospitalization for 35 days. The average Ribavirin was used at the discretion of the attending physician for therapy of infants with culture-proven RSV disease. One patient in the control group and no patient in the treated group received ribavirin therapy.
Adverse events. There were no major side effects from the immune globulin infusions. The most significant complication was difficulty starting the intravenous infusion. There were four deaths, one in the control group and three in the prophylaxis group. An extensive analysis of hospital and autopsy reports determined that no death occurred either from RSV infection or from intravenous immune globulin therapy (Table 3) .
Serology. Occult RSV infection as determined by IgA seroconversion (a fourfold or greater rise in IgA RSV antibody titer) did not occur in any of the 17 children from whom at least two serum specimens were available. The average peak neutralization titer 6 h postinfusion in four treated patients was 1:124. The average trough neutralization titer just prior to a subsequent infusion (28.7 days following infusion) was 1:57 in seven infants.
DISCUSSION
In the absence of a safe and effective means of active immunization, immune globulin holds the greatest promise for the prevention of severe RSV illness in high-risk children. Studies by Hemming and coworkers (11, 12, 19) have shown that immunoprophylaxis is effective in attenuating RSV disease in both the cotton rat and owl monkey animal models. Human immune globulin administered 1 day before intranasal challenge with RSV reduced pulmonary replication of RSV and, to a lesser extent, viral replication in the nasal mucosa (13) . These studies in animals suggest that serum neutralizing antibody titers of at least 1:200 are necessary to reduce viral replication in the lower respiratoxy tract (20) . In the present study, there was a trend toward fewer hospital days because of RSV infection in immune globulin recipients, although a significant benefit could not be demonstrated. This may have been due to failure to attain a sufficient titer of RSV neutralizing antibody or to an inadequate sample size.
The average peak titer achieved in our study was 1:124, with trough titers of 1:57. These are similar to those described by Groothuis and coworkers (6) , who used a similar dose of commercial immune globulin preparation in an open-label safety study. We found that while titers of less than 1:200 appear to be too low to induce complete protection of the lower airway, the possible attenuation of disease severity in the treated children suggested that higher RSV neutralizing antibody titers might result in a greater attenuation of illness caused by RSV. An alternative explanation for the inability to demonstrate a statistically significant benefit between the two groups is the relatively small number of patients studied. In our study, we had a 4.7-day difference between the immune globulin and control groups. In order to have an 80% chance of demonstrating a significant difference in the days of hospitalization between the two groups, 56 subjects would have been needed in each group.
The monthly doses of intravenous immune globulin were safe and well tolerated. The three deaths that occurred in treated patients were unrelated to intravenous immune globulin therapy. Furthermore, the RSV infections in infants who received immune globulin were no more severe than those in control children, as determined by the duration of hospitalization, suggesting that there was no enhancement of pulmonary disease such as that described with formalininactivated vaccine (2, 3, (12) (13) (14) .
The etiologic viral agent in bronchiolitis is identified in only two-thirds of patients from whom appropriate samples for culture are obtained (17) . Cultures in the remaining patients may be negative either because the virus has already been eradicated by the time a culture is obtained or because the illness is caused by a nonviral pathogen. A review of all infants hospitalized with bronchiolitis, including those from whom no viral agent was identified, found that immune globulin use was associated with 64% fewer days of hospitalization because of respiratory symptoms. This trend may have been due to a direct neutralizing effect by antibody in the immune globulin against an unrecovered organism or, alternatively, to a nonspecific immunoregulatory effect of the immune globulin. Intravenous immune globulin has been shown to affect several aspects of immune function which are important in viral inactivation such as cytokine secretion, natural killer cell activity, and B cell activity (22) .
The results of the present study suggest that standard intravenous immune globulin is safe in the high-risk population that we studied, but it may not contain sufficient RSV neutralizing antibody to ameliorate or prevent lower respi- VOL. 37, 1993 on August 27, 2017 by guest http://aac.asm.org/ Downloaded from ratory illness. It is possible that immune globulin containing a higher titer of RSV neutralizing antibody such as a hyperimmune globulin or monoclonal antibodies will be more effective at reducing serious RSV lower respiratory tract disease in high-risk young children.
